Business Context and Reporting Period
DBV Technologies S.A., a biopharmaceutical company developing epicutaneous immunotherapy (EPIT) for food allergies, reported its financial results for the first half of 2017 (ended June 30, 2017). The filing is a Form 6-K dated July 28, 2017, containing a press release summarizing interim results subject to a limited review by external auditors.
Key Financial Metrics
| Metric | First Half 2017 | First Half 2016 |
|---|---|---|
| Operating Income | €7.6 million | €4.8 million |
| Net Loss | €72.5 million | €49.4 million |
| Loss Per Share | €(2.94) | €(2.03) |
| Research & Development Expenses | €52.5 million | €32.9 million |
| Sales & Marketing Expenses | €8.5 million | €5.5 million |
| General & Administrative Expenses | €17.7 million | €15.8 million |
| Cash and Cash Equivalents (as of June 30, 2017) | €198.7 million | €256.5 million (as of Dec 31, 2016) |
Revenue: The filing text does not provide a clear value for total revenue, though it notes operating income was primarily generated by the Research Tax Credit and income from a collaboration agreement with Nestlé Health Science.
Material Changes Versus Prior Period
- Operating Income: Increased by 60% (€2.8 million) compared to the prior-year period.
- Net Loss: Widened by €23.1 million (47% increase) to €72.5 million.
- R&D Expenses: Increased by €19.6 million (60%) due to ongoing Phase III (Viaskin Peanut) and Phase II (Viaskin Milk) clinical trials and increased personnel.
- Sales & Marketing: Increased by €3.0 million (56%) driven by U.S. headcount growth and preparations for the potential North American launch of Viaskin Peanut.
- G&A Expenses: Increased by €1.9 million (12%) due to global headcount, legal/professional services, and NASDAQ-listing costs, partially offset by lower insurance expenses.
- Liquidity: Cash position decreased by €57.8 million from the end of 2016.
Outlook, Risks, and Management Commentary
Management highlighted the progression of clinical trials for Viaskin Peanut and Viaskin Milk as the primary drivers of expense increases. The company is also pursuing a human proof-of-concept study for Viaskin Milk in treating Eosinophilic Esophagitis and exploring vaccine applications. No specific forward-looking financial guidance or quantitative outlook was provided in this text. The filing notes the company is dedicated to transforming care for food allergic patients where no approved treatments currently exist.
Key Facts for Investor Verification
- Verify the specific revenue contribution from the Nestlé Health Science collaboration agreement versus the Research Tax Credit.
- Confirm the burn rate and projected runway based on the €57.8 million cash decrease in six months.
- Review the detailed status and enrollment numbers for the Phase III Viaskin Peanut and Phase II Viaskin Milk trials.
- Assess the timeline and regulatory requirements for the potential North American launch of Viaskin Peanut.
- Examine the full interim financial report for a complete breakdown of operating expenses and cash flow statements.